6.0(top 5%)
impact factor
2.0K(top 10%)
papers
74.4K(top 5%)
citations
115(top 5%)
h-index
6.2(top 5%)
impact factor
2.6K
all documents
81.0K
doc citations
180(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Deconstructing the molecular portraits of breast cancerMolecular Oncology20111,059
2MicroRNA and cancerMolecular Oncology2012963
3Emerging functions of the EGFR in cancerMolecular Oncology2018927
4The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expressionMolecular Oncology2007872
5The role of histone deacetylases (HDACs) in human cancerMolecular Oncology2007796
6The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandingsMolecular Oncology2011664
7Imaging and cancer: A reviewMolecular Oncology2008613
8Cancer biomarkersMolecular Oncology2012600
9Epithelial–mesenchymal transition in tumor metastasisMolecular Oncology2017511
10Discovery of small molecule cancer drugs: Successes, challenges and opportunitiesMolecular Oncology2012447
11Circulating tumor cell technologiesMolecular Oncology2016432
12EMT and inflammation: inseparable actors of cancer progressionMolecular Oncology2017426
13Targeting immunogenic cell death in cancerMolecular Oncology2020383
14Histone deacetylases and cancerMolecular Oncology2012373
15Histological types of breast cancer: How special are they?Molecular Oncology2010365
16Early‐onset colorectal cancer in young individualsMolecular Oncology2019365
17Tumour heterogeneity and the evolution of polyclonal drug resistanceMolecular Oncology2014347
18New insights into the role of EMT in tumor immune escapeMolecular Oncology2017332
19Exosome‐delivered circRNA promotes glycolysis to induce chemoresistance through the miR‐122‐PKM2 axis in colorectal cancerMolecular Oncology2020327
20Targeted proteomic strategy for clinical biomarker discoveryMolecular Oncology2009321
21EMT and MET: necessary or permissive for metastasis?Molecular Oncology2017319
22Frequent expression of PD‐L1 on circulating breast cancer cellsMolecular Oncology2015303
23The circRNA–microRNA code: emerging implications for cancer diagnosis and treatmentMolecular Oncology2019300
24Genetic susceptibility to breast cancerMolecular Oncology2010291
25The biology of cancer testis antigens: Putative function, regulation and therapeutic potentialMolecular Oncology2011281
26HDAC inhibitor‐based therapies: Can we interpret the code?Molecular Oncology2012271
27Cell‐to‐cell communication: microRNAs as hormonesMolecular Oncology2017267
28ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration, and invasion but through different signaling pathwaysMolecular Oncology2017259
29Triple‐negative breast cancer: Present challenges and new perspectivesMolecular Oncology2010252
30Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor typesMolecular Oncology2015248
31Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cellsMolecular Oncology2015245
32The epigenetics of breast cancerMolecular Oncology2010242
33Challenges in circulating tumor cell detection by the CellSearch systemMolecular Oncology2016231
34Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body siteMolecular Oncology2008228
35DNA methylation and microRNA dysregulation in cancerMolecular Oncology2012228
36Biobanking for better healthcareMolecular Oncology2008224
37Transfection of chimeric anti‐CD138 gene enhances natural killer cell activation and killing of multiple myeloma cellsMolecular Oncology2014215
38Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanismsMolecular Oncology2021210
39Trials with ‘epigenetic’ drugs: An updateMolecular Oncology2012208
40Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosisMolecular Oncology2007206
41EMT: Present and future in clinical oncologyMolecular Oncology2017205
42Exosomal proteins as prognostic biomarkers in non‐small cell lung cancerMolecular Oncology2016202
43Progression from ductal carcinoma in situ to invasive breast cancer: RevisitedMolecular Oncology2013195
44Multi‐marker analysis of circulating cell‐free DNA toward personalized medicine for colorectal cancerMolecular Oncology2014192
45Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530Molecular Oncology2009190
46Drug resistance to targeted therapies: Déjà vu all over againMolecular Oncology2014187
47Circulating and disseminated tumor cells: harbingers or initiators of metastasis?Molecular Oncology2017182
48Determinants of metastatic competency in colorectal cancerMolecular Oncology2017180
49The Contribution of BRCA1 and BRCA2 to Ovarian CancerMolecular Oncology2009178
50Mass spectrometry based biomarker discovery, verification, and validation — Quality assurance and control of protein biomarker assaysMolecular Oncology2014178